Evonik stock holds near yearly highs as investors look to guidance and specialty chemicals growth

Published on 09/01/2026 at 20:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evonik stock remains firm near its 2026 highs, with a strong year-to-date performance on Tradegate and investors focusing on the specialty chemicals group’s latest guidance and margin trends. The MDAX-listed company continues to benefit from portfolio streamlining and growth in key segments.

Draufsicht auf Aktienzertifikat, ISIN-Karte DE000EVNK013 und Spezialchemie-Laborutensilien auf Marmor — Evonik Industries DE000EVNK013 als Flatlay mit Aktienzertifikat, ISIN-Karte und Chemielabor-Utensilien auf Marmor, Illustration mit AI erstellt.

Evonik Industries stock (ISIN DE000EVNK013) is trading at EUR 18.92 on the Tradegate platform as of August 31, 2026, reflecting a 0.75 percent gain for the day and a 40.78 percent increase since the start of the year according to a recent market snapshot from Ad Hoc News dated August 31, 2026.

Strong 2026 share performance supports Evonik stock

According to the Tradegate data cited on August 31, 2026, Evonik shares changed hands at EUR 18.92, up 0.75 percent for the session, with a year-to-date gain of 40.78 percent that places the stock clearly ahead of many traditional chemical peers listed in Germany.

The same snapshot notes that the stock has held its recent gains, trading close to its 2026 highs, which suggests that investors continue to price in the specialty chemicals group’s restructuring progress and its shift toward higher-margin businesses, even as the broader European chemicals sector remains mixed.

Latest reported figures and investor focus

Based on the most recent half-year reporting referenced by financial portals in 2026, Evonik’s latest interim results showed that revenue in the most recent reported quarter was modestly higher than in the prior-year period, while profitability improved more clearly, with operating earnings rising by a double-digit percent rate compared with the same quarter a year earlier; these figures are presented as part of the company’s latest available interim report in 2026 and form the current reference point for analysts.

In that same reporting context for the latest quarter in 2026, Evonik’s adjusted earnings before interest, taxes, depreciation and amortization increased year on year by a mid-teen percent rate, driven mainly by improved margins in specialty additives and nutrition businesses, while more cyclical segments such as performance materials remained under pressure; this quantified improvement relative to the prior-year quarter is central for many investors when assessing the sustainability of the stock’s 40.78 percent year-to-date advance.

Go deeper

More background on Evonik

Additional news, charts and regulatory filings for Evonik can be found in the dedicated topic overview on ad-hoc-news.de.

All Evonik reports at ad-hoc-news.de Investor Relations

Specialty chemicals and lipid products in focus

Evonik Industries is best known for its specialty chemicals portfolio, including lipid products used as critical components in pharmaceutical formulations and advanced drug delivery, which have become more prominent in recent years as the company invested in new production capacity in North America and Europe.

These higher-value products typically carry better margins than bulk chemicals and, according to the latest 2026 interim figures, contribute to the company’s improved profitability relative to the prior-year period, making the development of these lines an important factor for how investors judge the durability of current earnings trends.

Evonik stock on the German market

Evonik stock is listed on Xetra under the ticker EVK, with the latest referenced Tradegate quote of EUR 18.92 as of August 31, 2026 serving as a recent trading level for investors who track the MDAX and related German mid-cap indices.